MedChemWatch
Monthly Newsletter March 2016

12th EFMC Short Course on Medicinal Chemistry - "Modulation of Enzymes; Epigenetics and Beyond", April 24-27, 2016 - Oegstgeest (near Leiden), The Netherlands

In 2009, EFMC launched a series of short courses aimed to favour cultural and scientific growth of the medicinal chemistry community and organised with affordable fees for participation. This years' edition is dedicated to "Modulation of Enzymes; Epigenetics and Beyond".

This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants will be limited to 35, to favour in depth discussion. 

Speakers

  • The PDE Family and Inhibitors
    Dr Andrew BELL (Iperial College London, United Kingdom)
  • Epigenetic Target Families in Medicinal Chemistry
    Prof. Paul BRENNAN (University of Oxford, United Kingdom)
  • Brodomain Inhibitors - from Phenotypic Screens to Fragments
    Dr Chun-wa CHUNG (Glaxosmithkline R&D, United Kingdom)
  • Fragment-Based Lead Generation
    Prof. Iwan DE ESCH (VU University Amsterdam, The Netherlands)
  • Glycomimetics - an Underexplored Compound Class for Medicinal Chemistry
    Prof. Dr Beat ERNST (University of Basel, Switzerland)
  • Proteasome Inhibitors
    Prof. Michael GROLL (Technische Universität Munchen, Germany)
  • Basic Principles of Enzymology
    Dr Laurie LEBRUN (Celgene, United States)
  • Kinases and Inhibitors
    Dr Gerhard MÜLLER (Mercachem, The Netherlands)
  • The Protease Target Family
    Dr Holger SELLNER (Novartis, Switzerland)
  • Parallel Hands on Tutorials - Cases Study I
    Dr Leon VAN BERKOM (Mercachem, The Netherlands)
    Dr Toine VAN DEN BERGH (Mercachem, The Netherlands)
  • Parallel Hands on Tutorials - Cases Study II
    Dr Stijn GREMMEN (Mercachem, The Netherlands)
    Dr Harald ALBERS (Mercachem, The Netherlands)

Find out more about the scientific programme.

Course outline

Enzymes encompass a vast number of distinct target families relevant for contemporary medicinal chemists‘ endeavor to the discovery of efficient and safe drugs. A recent analysis of about 1.000 drugs approved from 1982 – 2010 uncovered around 450 effect-mediating drug targets of which only 150 cluster into enzyme families. However, the ratio of enzyme inhibitors among all approved drugs has increased over the last 10 years; of all ‘true NCEs’ that reached the market from 2005 onwards, more than 50% exert their therapeutic effect by modulation of human and pathogenic enzymes. Many of the approved inhibitors modulate enzymes that cluster into densely populated target families that will be scrutinized in the 12th EFMC Short Course on Medicinal Chemistry. Hence, the focus of this course will be centered on all aspects of enzyme inhibitor discovery addressing the widely unexploited potential of both, the established enzyme classes such as proteases and kinases, as well as the modern emerging enzyme families from e.g. the epigenetics area.  A collection of renowned international experts in the field will highlight various methodological, technological, and enzymological aspects of medicinal chemistry aimed at the discovery of inhibitors against proteases, kinases, phosphodiesterases, as well as epigenetic targets, respectively. Lectures and discussions will be complemented by interactive hands-on sessions on selected case studies in which the participants will be challenged to pursue  hit-to-lead and subsequent lead optimization campaigns, supervised by experienced medicinal chemists.

Course Organisers
Gerhard Müller (Mercachem, The Netherlands)
Anita Wegert (Mercachem, The Netherlands)

Local Organiser
Henk TIMMERMAN (VU University Amsterdam, The Netherlands)

Find out more on: www.efmcshortcourses.org

News from the French Society of Therapeutic Chemistry (SCT)

The SCT is pleased to announce

  • the 52nd International Conference on Medicinal Chemistry (RICT 2016: Interfacing Chemical Biology and Drug Discovery.) that will take place in Caen, France from July 6 until 8, 2016.
  • The Pierre Fabre Award for Therapeutic Innovation.

RICT 2016: Interfacing Chemical Biology and Drug Discovery. 52nd International Conference on Medicinal Chemistry. Caen, France - July 6-8, 2016

The French Medicinal Chemistry Society (Société de Chimie Thérapeutique – SCT, www.sct-asso.fr) is pleased to invite you to Caen (Normandy), France on July 6-8, 2016 for the 52nd edition of the International Conference on Medicinal Chemistry (RICT 2016). Prof. Patrick Dallemagne, head of the Local Organising Committee, will welcome you in the city of William the Conqueror, Duke of Normandy and King of England.

The congress will be devoted to “Interfacing Chemical Biology and Drug Discovery” and the main topics will be:

  • Approaches for Target Identification-Validation
  • Biomarkers – Innovative Diagnostic Approaches, Tools
  • Molecular Diversity
  • Chemoinformatics in and for Drug Discovery
  • Therapeutic Interventions Targeting the Nervous System
  • Case Studies (all targets and therapeutic indications included)

Additionally you will be able to appreciate the climate of the beautiful Normandy and visit the famous Mont-Saint-Michel, its wild coast with its lighthouses, the D-Day historic sites and beaches, the green countryside (here the highland named Norman Switzerland) or the lovely Alabaster seaside with the famous Etretat beach. Caen is located at 230 kilometers from Paris and easily accessible by car, train, plane or even by boat (Caen - Ouistreham harbour).

Confirmed speakers and topics:

http://www.sct-asso.fr/wa_files/ConfirmedSpeakers-1607b_RICT_2016.pdf

Register on:

http://www.ldorganisation.com/v2/register_new.php?langue=english&cle_menus=1238916167&cle_data=1360153449


The "Pierre Fabre Award for Therapeutic Innovation"


The aim and the spirit of the award

Pierre Fabre, founder of the Laboratories Pierre Fabre, second independent pharmaceutical company in France, was a self-entrepreneur highly motivated and passionate of science, pharmaceutical research for the benefit of patient and human being.
He was a visionary manager and until the last moment of his life involved in developing the pharmaceutical activities, while being very close to his associates.
The name of “Pierre Fabre” definitively being associated with the spirit of “Therapeutic innovation”, the company “Pierre Fabre Médicament”, in memory of its founder, and in partnership with the French Medicinal Chemistry Society, has decided awarding a decisive action, a scientific discovery, an innovative technology contributing to a substantial therapeutic innovation. This contribution may rise from the very early phase of research and would like to nominate a talented researcher.
Individual Candidacies should be mailed to the SCT secretary,  alain.gueiffier@univ-tours.fr

The deadline for submission is May 1st., 2016.

The candidates should provide a short document (font: Arial 12, space between lines: 1.15) describing their own contribution to innovation, including the state of art, the context and the exceptional added value of the innovation, the potential impact on the downstream phases, the perspectives, the references. In addition a short CV of the candidate should be added. The total length of this document (Contribution+ refs+CV) should not exceed 10 printed pages.

The candidate has to accomplish its duty as SCT member by paying his membership by credit card on the SCT website to be eligible. The “Pierre Fabre award” jury members select the laureate among the candidates.

The “Pierre Fabre Award for Therapeutic Innovation” (amount of 3000 €) is given during the International Conferences of Medicinal Chemistry (RICT), an annual SCT meeting, by a Pierre Fabre company representative and the SCT president.

By accepting the award, the laureate agrees to present a plenary lecture at the RICT 2016 (July 6-8, 2016, Caen, Normandy).
 
List of Laureates

In 2014, the Pierre FABRE Award for Therapeutic Innovation went to Prof. Sébastien PAPOT
In 2015, the Pierre FABRE Award for Therapeutic Innovation went to Dr Raphaël RODRIGUEZ

Information for this call can also be found at: www.sct-asso.fr/prix_pierre_fabre.html

To follow all SCT activities: www.sct-asso.fr

News from the Spanish Society of Medicinal Chemistry (SEQT)

The Spanish Society of Medicinal Chemistry (SEQT) is pleased to announce:

  • the Fifth SEQT Summer School "Medicinal Chemistry in Drug Discovery: the Pharma Perspective" that will take place on June 14-16, 2016 in Sant Feliu de Llobregat (Barcelona), Spain
  • the 3rd SEQT YOUNG RESEARCHERS SIMPOSIUM that will take place on June 17th, 2016 in Barcelona, Spain
  • the "Medicinal Chemistry of Tropical Diseases: XII SEQT Mini Symposium". IIIrd Spanish/Portuguese/Brazilian Meeting that will take place on November 17-18, 2016 in Tres Cantos (Madrid), Spain

Fifth SEQT Summer School "Medicinal Chemistry in Drug Discovery: the Pharma Perspective", June 14-16, 2016 - Sant Feliu de Llobregat (Barcelona), Spain

The Fifth SEQT Summer School “Medicinal Chemistry in Drug Discovery: The Pharma Perspective” will be organized by the Spanish Society of Medicinal Chemistry (SEQT) and Almirall with the aim of approaching the pharma industry to young researchers, both graduate students and post-doctoral associates, working in chemistry and health sciences related fields. The School will be held at Almirall facilities in Sant Feliu de Llobregat (Barcelona) in June 14-16 of 2016. The scientific program will be illustrated through real case studies led by an exceptional panel of industry experts currently working at Almirall, Esteve, GlaxoSmithKline, ABAC Therapeutics and Janssen.

To find out more, check the website www.seqt.org


3rd SEQT Young Researchers Symposium,
June 17th, 2016 - Barcelona (Spain)

The Spanish Society of Medicinal Chemistry (SEQT) has the pleasure to invite you to join the 3rd SEQT YOUNG RESEARCHERS SIMPOSIUM 2015. The meeting will take place at the Parc Cientific (Barcelona) the 17th of June 2016. At this event, young scientists (Master and PhD students as well as Postdocs) will have the opportunity to present their work in the form of oral or poster presentations.

For further information and regular updates, please visit our website www.seqt.org


Medicinal Chemistry of Tropical Diseases: XII SEQT Mini Symposium. IIIrd Spanish/Portuguese/Brazilian Meeting, November 17-18, 2016 - Tres Cantos (Madrid), Spain

The Spanish Society of Medicinal Chemistry (SEQT) is organizing the XIIth SEQT Mini Symposium. IIIrd Spanish/Portuguese/Brazilian Meeting, scheduled to be held on November 17-18th 2016 at GSK R&D facilities in Tres Cantos (Madrid, Spain). The topic of this joint meeting will be

Medicinal Chemistry of Tropical Diseases

The Scientific Program will include invited plenary lectures, oral communications and, flash presentation (1-2 slides) sessions.

Updated information will be available at our website: www.seqt.org

News from the Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC)

The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) is pleased to announce:

  • the Joint RSC-BMCS and RSC-H&SG Meeting on Synthesis in the Agrisciences that will take place on April 14th 2016 in London, UK
  • Kinase 2016:  7th RSC / SCI symposium on Kinase Inhibitor Design that will take place on May 16th, 2016 in Nottingham, UK

Joint RSC-BMCS and RSC-H&SG Meeting on Synthesis in the Agrisciences on 14th April 2016, RSC, London, UK

Synopsis:  The objective of the meeting is to promote scientific interactions between researchers in the field and to showcase the key role that synthesis plays in the development of new agrochemicals. New crop protection products are important tools for overcoming the huge challenges that modern agriculture faces – to increase food production and yield in a cost effective and sustainable manner with limited farmland and water supplies and loss of existing solutions through development of resistance or regulatory pressures.

Website:  http://www.rsc.org/events/detail/20919/rsc-bmcs-handsg-symposium-synthesis-in-the-agrisciences

 

Kinase 2016:  7th RSC / SCI symposium on Kinase Inhibitor Design on 16th May 2016, Nottingham, UK

Synopsis:  Perturbation of cell signalling through inhibition of kinase enzymes has delivered nearly 30 approved medicines to date. The meeting will feature several highly pertinent themes including new approaches and technologies to modulate and measure kinase function as well as diverse medicinal chemistry case studies. The symposium will also draw on the lessons from history to provide insight into the future direction of the field.

Website:  http://www.rsc.org/events/detail/19885/kinase-2016-next-generation-inhibitors 

 

EFMC ORGANISED EVENTS

September 6-7, 2018
Ljubljana, Slovenia
5th EFMC Young Medicinal Chemist Symposium (EFMC-YMCS 2018)

EFMC SPONSORED EVENTS

January 28 - February 1, 2018
St Anton, Austria
1st Alpine Conference on Medicinal and Synthetic Chemistry

JOB PORTAL

Early Stage Researcher in Medicinal Chemistry, University of Basel (UNIBAS), University of Utrecht (UU), PamGene: Department of Pharmaceutical Sciences (UNIBAS), Department of Chemical Biology & Drug Discovery (UU), Basel, Utrecht, 's-Hertogenbosch, Switzerland
Read more


Early Stage Researcher in Medicinal Chemistry, University of Ljubljana (UL), University of Utrecht (UU), PamGene: Faculty of Pharmacy, Chair of Pharmaceutical Chemistry (UL), Department of Chemical Biology & Drug Discovery (UU), Ljubljana, Utrecht, 's-Hertogenbosch, Slovenia
Read more


Early Stage Researcher in Medicinal Chemistry, University of Utrecht (UU), University of Ljubljana (UL), PamGene: Department of Chemical Biology & Drug Discovery (UU), Faculty of Pharmacy, Chair of Pharmaceutical Chemistry (UL), Utrecht, Ljubljana, 's-Hertogenbosch, The Netherlands
Read more


Early Stage Researcher in Medicinal Chemistry, University of Basel (UNIBAS), University of Ljubljana (UL): Department of Pharmaceutical Sciences (UNIBAS), Faculty of Pharmacy, Chair of Pharmaceutical Chemistry (UL), Basel, Ljubljana, Switzerland
Read more


Early Stage Researcher in Medicinal Chemistry, University of Ljubljana (UL), Lund University (ULUND), SARomics, Red Glead: Faculty of Pharmacy, Chair of Pharmaceutical Chemistry (UL), Department of Chemistry (ULUND), Ljubljana, Slovenia
Read more


Early Stage Researcher in Medicinal Chemistry, Università degli Studi di Milano (UMIL), Universiteit Utrecht (UU), PamGene: Chemistry (UMIL), Department of Chemical Biology & Drug Discovery (UU), Milano, Utrecht, 's-Hertogenbosch, Italy
Read more


Early Stage Researcher in Medicinal Chemistry, Università degli Studi di Milano (UMIL), Université Grenoble Alpes (UGA), Centre national de la recherche scientifique (CNRS-Glycopedia): Chemistry (UMIL), CERMAV (UGA), Milano, Gières, Grenoble, Italy
Read more


Early Stage Researcher in Medicinal Chemistry, Université Grenoble Alpes (UGA), Universiteit Utrecht (UU), PamGene: CERMAV (UGA), Department of Chenical Biology & Drug Discovery (UU), Gières, Utrecht, 's-Hertogenbosch, France
Read more


Early Stage Researcher in Medicinal Chemistry, Universiteit Utrecht (UU), Université Grenoble Alpes (UGA), Centre national de la recherche scientifique (CNRS): Department of Chemical Biology & Drug Discovery (UU), CERMAV (UGA), Utrecht, Gières, Grenoble, The Netherlands 
Read more


Early Stage Researcher in Medicinal Chemistry Université Grenoble Alpes (UGA), Università degli Studi di Milano (UMIL), Centre national de la recherche scientifique (CNRS) : CERMAV (UGA), Department of Chemistry (UMIL), Gières, Milano, Grenoble, France
Read more


Research / Senior Scientist Medicinal Chemistry, UCB: Medicinal Chemistry, Braine-L'Alleud, Belgium
Read more


Principal Scientist Medicinal Chemistry, UCB: Medicinal Chemistry, Braine-L'Alleud, Belgium
Read more


Medicinal / Synthetic Organic Chemists, Concept Life Sciences: Drug Discovery, Sandwich, Kent, United Kingdom
Read more

Find us on social media

EFMC Facebook EFMC Twitter EFMC LinkedIn

EFMC